Clinical Trial Update: Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD [NA]

View source ↗

Summary

A clinical trial investigating adjunctive photodynamic therapy with aflibercept for neovascular age-related macular degeneration has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Verteporfin (verteporfin)

Snippet

Sponsor: Duke University | Conditions: Neovascular Age-related Macular Degeneration | NA | Status: WITHDRAWN